To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
A. G. Lafley
Alan George "A.G." Lafley (born June 13, 1947) is an American businessman who serves as the CEO, President, and the Chairman of the Board of Procter & Gamble. He succeeded Durk Jager in June 2000, after the Board of Directors reportedly pressured Jager to resign [3]. Previously, Lafley had been President of Global Beauty Care and North America for P&G. Additional recommended knowledgeLafley graduated from Fenwick High School in Oak Park, Illinois, to earn an B.A. from Hamilton College in 1969. In 1970, after beginning a doctoral program, he took a commission with the U.S. Navy as a supply officer during the Vietnam War. Afterwards, he studied at Harvard Business School, receiving his M.B.A. in 1977. He joined P&G upon his graduation, where he has worked ever since. He is credited with revitalizing the company[4] by focusing on successful P&G brands like Crest, Tide, and Pampers instead of trying to develop new brands[5]. Some of the turning points of Lafley's career include P&G's acquisition of the Crest electric toothbrush [1]. Lafley's handling of Crest allowed it to regain a foothold in the oral hygiene business from Colgate in 1998[6]. Along with Procter & Gamble, Lafley is also a member of the General Electric board of directors. Lafley was named the chairman of Hamilton's Board of Trustees in December 2007.[7] References
|
||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "A._G._Lafley". A list of authors is available in Wikipedia. |
- Quisqualic_acid
- Exposure to traffic noise linked to higher dementia risk - Reducing noise is a public health priority, say experts
- Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis - SELECT Study Demonstrates Significant Reductions in Annualized Relapse Rate and Meets Key Secondary Endpoints
- Netochka_Nezvanova
- Superbug study reveals how E. coli strain acquired deadly powers